MGH Onconephrology

We conduct patient-oriented research to address kidney care in patients with cancer. Run by @MegSise

[Raad Chowdhury, MD, FASN @rc_oncneph]

Congrats @DavidLeaf9 @ShrutiGkidney @MGH_Onconeph et al !

@onconephsociety

[Paul E. Hanna, MD, MSc, FASN @PaulHannaMD]

📣 After 3 wonderful years @MCW_Nephrology, I have transitioned into a new role @MayoClinicNeph in FL.
Grateful for my time and wonderful colleagues at MCW and genuinely excited for what’s ahead at Mayo
#Onconephrology

[Raad Chowdhury, MD, FASN @rc_oncneph]

Kudos to @PaulHannaMD and his team for tirelessly working on this. I remember we were fellows when Paul started developing this concept.

[Raad Chowdhury, MD, FASN @rc_oncneph]

To start Dr. @HerrmannMd on Nephrotoxicities of Cancer Drugs

#onconephsymposium2025
@onconephsociety
@MayoClinicNeph

[Paul E. Hanna, MD, MSc, FASN @PaulHannaMD]

Great presentation @onconeph on eGFR in patients with cancer @MayoClinicNeph onconephrology symposium!

Thanks for highlighting our work and special thanks @MegSise for leading the way! @MCW_Nephrology @MGBKidneys @MGH_Onconeph

[AJKD @AJKDonline]

Eculizumab Prophylaxis for Systematic Rechallenging Gemcitabine in Gemcitabine-Induced Thrombotic Microangiopathy: A Case Report

https://t.co/hBVM6KITJv

@Api_chew @ShrutiGkidney @rc_oncneph

[Sandra Herrmann MD, FASN @HerrmannMd]

Complement Inhibition Enables Anti-VEGF Receptor Therapy in Renal-Limited TMA. More options to keep patients on life-saving therapy.
Check it out.👇🏽⁦@ISNeducation⁩
⁦@delphile⁩ ⁦@KIReports⁩ @AbdullahJalalMD⁩ ⁦@MayoClinicNeph⁩ https://t.co/3V0EwggomR

[Jamie Lin MD FASN @JamieLinMD]

Wrestling immune nephritis with a JAK-STAT inhibitor! Read about our experience using Tofacitinib 💊 to treat refractory ICI-nephritis. #PatientCare #immunotherapy #immunotoxicity
@MDAndersonNews @onconephsociety @ASNKidney @womeninnephro

https://t.co/riS5ytYV9s

[American Society of Onconephrology @onconephsociety]

Management of acute kidney injury in tumor lysis syndrome: a narrative review | Internal and Emergency Medicine https://t.co/BnML4npBw0

[Paul E. Hanna, MD, MSc, FASN @PaulHannaMD]

Curious about striated nephrogram in patients receiving ICI for #Cancer ?

We hope our latest work helps shed some light on this interesting imaging finding.

@MegSise @MGBKidneys @BetterCallSeeth @MCW_Nephrology @MGH_Onconeph @onconephsociety

https://t.co/2bkySzkDKP

[Kenar Jhaveri @kdjhaveri]

🧵 14/ Congratulations to everyone involved in this herculean study, including @ShrutiGKidney, @DavidLeaf9, @IlyaGlezerman , @jam_hirsch , @Api_chew , @M_Abramson @HofstraKidney @BWHkidney @MSK_Neph @ISMMSKidney
@MDAndersonNews @CU_Kidney

[MGH Onconephrology @MGH_Onconeph]

Missed our late breaking PO presentation at NKF? Here is a quick recap by our very own @MegSise @MGHCancerCenter @MGHKidneys https://t.co/aDwHmN78G9

[Si Yuan Khor @SiYuanKhor1]

Excited to present our group work and preliminary data on re-defining carboplatin dosing by utilizing different GFR equations at NKF. Grateful for the opportunity! @MegSise @MGH_Onconeph

[Paul E. Hanna, MD, MSc, FASN @PaulHannaMD]

Had the pleasure of presenting our work on personalizing eGFR in patients with cancer #NKFClinicals @NKF_NephPros @MegSise @MCW_Nephrology @MGH_Onconeph @MGHKidneys

[MGH Onconephrology @MGH_Onconeph]

Full house @nkf #NKFClinicals for PO presentations! Our very own Si Yuan kicked off the session with an amazing talk about eGFR in patients with cancer receiving Carboplatin @MegSise

[Paul E. Hanna, MD, MSc, FASN @PaulHannaMD]

Kick off @NKF_NephPros pre-course: session #1 ICI- AIN @dmoledina @MegSise @BetterCallSeeth @MGH_Onconeph @MGHKidneys

[Kenar Jhaveri @kdjhaveri]

Evolving Practices in Immune-Related Adverse Event Management: Insights From the IMMUCARE Multidisciplinary Board | JCO Oncology Practice https://t.co/Frhh3DUtk6

[Anushree Shirali @anushreeshirali]

Great review by @onconeph, @HerrmannMd and others in this ongoing OncoNeph series in K360.

[Kenar Jhaveri @kdjhaveri]

Glucagon-like Peptide-1 Agonists Reduce Cardiovascular Events in Cancer Patients on Immune Checkpoint Inhibitors https://t.co/92S8w5olIq